CD19 and neoplasm: In this context, Lohmueller et al. designed an anti-biotin CAR-T cell and administered it with biotinylated bispecific antibody (anti-CD19 or anti-CD20) coated on tumor cells, which exhibited the higher induced function of CAR-T cell, IFN-γ production, and tumor cell eradication.